Publication
Cetuximab plus platinum-based chemotherapy in head and neck Squamous Cell Carcinoma: a retrospective study in a single Comprehensive European Cancer Institution
| dc.contributor.author | De Mello, Ramon Andrade | |
| dc.contributor.author | Gerós, Sandra | |
| dc.contributor.author | Alves, Marcos Pantarotto | |
| dc.contributor.author | Moreira, Filipa | |
| dc.contributor.author | Avezedo, Isabel | |
| dc.contributor.author | Dinis, Jose | |
| dc.date.accessioned | 2018-12-07T14:53:04Z | |
| dc.date.available | 2018-12-07T14:53:04Z | |
| dc.date.issued | 2014-02 | |
| dc.description.abstract | Background: The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN). We investigated the efficacy and outcome of this protocol as a first-line treatment for patients with recurrent or metastatic disease. We evaluated overall-survival (OS), progression-free-survival (PFS), overall response rate (ORR) and the treatment toxicity profile in a retrospective cohort. Patients and Methods: This study enrolled 121 patients with untreated recurrent or metastatic SCCHN. The patients received PF+ cetuximab every 3 weeks for a maximum of 6 cycles. Patients with stable disease who received PF+ cetuximab continued to receive cetuximab until disease progressed or unacceptable toxic effects were experienced, whichever occurred first. Results: The median patient age was 53 (37-78) years. The patient cohort was 86.8% male. The addition of cetuximab to PF in the recurrent or metastatic setting provided an OS of 11 months (Confidential Interval, CI, 95%, 8.684-13.316) and PFS of 8 months (CI 95%, 6.051-9.949). The disease control rate was 48.9%, and the ORR was 23.91%. The most common grade 3 or 4 adverse events in the PF+ cetuximab regimen were febrile neutropenia (5.7%), skin rash (3.8%) and mucosistis (3.8%). Conclusions: The results of this study suggest that cetuximab plus platinum-fluorouracil chemotherapy is a good option for systemic treatment in advanced SSCHN patients. This regimen has a well-tolerated toxicity profile. | |
| dc.description.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1371/journal.pone.0086697 | |
| dc.identifier.issn | 1932-6203 | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/11334 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Public Library of Science | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Clinical-practice guideline | |
| dc.subject | Phase-Ii multicenter | |
| dc.subject | 1St-line treatment | |
| dc.subject | Antibody cetuximab | |
| dc.subject | Induced nausea | |
| dc.subject | Recurrent | |
| dc.subject | Association | |
| dc.subject | Cisplatin | |
| dc.subject | Polymorphism | |
| dc.subject | Trial | |
| dc.title | Cetuximab plus platinum-based chemotherapy in head and neck Squamous Cell Carcinoma: a retrospective study in a single Comprehensive European Cancer Institution | |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 2 | |
| oaire.citation.startPage | e86697 | |
| oaire.citation.title | PLoS ONE | |
| oaire.citation.volume | 9 | |
| person.familyName | de Mello | |
| person.givenName | Ramon Andrade | |
| person.identifier.orcid | 0000-0002-9640-4573 | |
| rcaap.rights | openAccess | |
| rcaap.type | article | |
| relation.isAuthorOfPublication | 53ee625f-c5c3-468b-85bb-4cef5ad36928 | |
| relation.isAuthorOfPublication.latestForDiscovery | 53ee625f-c5c3-468b-85bb-4cef5ad36928 |
Files
Original bundle
1 - 1 of 1